City of Hope Medical Center
AutoCD6-CAR Treg cells(City of Hope Medical Center)은 Stage 3 Type 1 Diabetes 표적 세포·유전자 치료로, Stage 3 Type 1 Diabetes 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel therapeutic approaches for AD.
Stage 3 Type 1 Diabetes
Stage 3 Type 1 Diabetes
Recruiting
CAR therapies as a strategy to retain potent anti-leukemic activi
AAV gene transfer, effectively target the primary enzymatic deficit, neuroinflammat
novel therapeutic approaches for AD
checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo
T cells, reduced Th17 recruitment
apoptosis, enhance autophagic flux, and suppress invasion and metastasis by regulating Wnt/β-catenin, PI3K/AKT/mTOR, MAPK,
biomarker
downregulation of NF-κB/p65 and NLRP3 components and upregulation of arginase 1 mRNA after 48 h of treatment
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
City of Hope Medical Center
AutoCD6-CAR Treg cells(City of Hope Medical Center)은 Stage 3 Type 1 Diabetes 표적 세포·유전자 치료로, Stage 3 Type 1 Diabetes 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel therapeutic approaches for AD.
Stage 3 Type 1 Diabetes
Stage 3 Type 1 Diabetes
Recruiting
CAR therapies as a strategy to retain potent anti-leukemic activi
AAV gene transfer, effectively target the primary enzymatic deficit, neuroinflammat
novel therapeutic approaches for AD
checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo
T cells, reduced Th17 recruitment
apoptosis, enhance autophagic flux, and suppress invasion and metastasis by regulating Wnt/β-catenin, PI3K/AKT/mTOR, MAPK,
biomarker
downregulation of NF-κB/p65 and NLRP3 components and upregulation of arginase 1 mRNA after 48 h of treatment
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.